Marek’s disease virus (MDV), a causative agent of Marek’s disease, has evolved its virulence partly because the current control strategies fail to provide sterilizing immunity. Gallid alphaherpesvirus 3 (GaHV-3) and turkey herpesvirus have been developed as bivalent vaccines to improve upon the level of protection elicited by single formulations. Since the in vitro passage of vaccines can result in attenuation, a GaHV-3 strain 301B/1 was cloned as a bacterial artificial chromosome (BAC) by inserting the mini-F replicon into the virus genome. A fully infectious virus, v301B-BAC, was reconstituted from the 301B/1 BAC clone and had similar growth kinetics comparable to that of the parental 301B/1 virus with strong reactivity against anti-301B/1 chicken sera. Protective efficacies of v301B-BAC, parental 301B/1, and SB-1 vaccine were evaluated against a very virulent MDV Md5 challenge. Clinical signs were significantly lower in the v301B-BAC vaccinated groups (24–25 %), parental 301B/1 (29 %) compare to that of non-vaccinated control (100%) and the removal of BAC sequences from v301B-BAC genome further reduced this to 17 %. The protective indices of v301B-BACs (75–76 %) were comparable with those of both the 301B/1 and the SB-1 vaccine (71%). Removal of the mini-F replicon resulted in a reconstituted virus with a protective index of 83 %. The shedding of challenge virus was notably lower in the v301B-BAC, and v301B-delBAC vaccinated groups. Overall, the protective efficacy of the 301B-BAC-derived vaccine virus against a very virulent MDV challenge was comparable to that of the parental 301B/1 virus as well as the SB-1 vaccine virus.
WitterRL.
Characteristics of Marek's disease viruses isolated from vaccinated commercial chicken flocks: association of viral pathotype with lymphoma frequency. Avian Dis1983; 27:113–132 [View Article][PubMed]
JackwoodWM,
HickleL,
KapilS,
SilvaR.
Vaccine development using recombinant DNA technology. Council for Agricultural Science and Technology2008; 38:1–12
AudonnetJ-C,
BublotM,
DarteilR,
DuinatC,
LaplaceE et al.Avian Herpesvirus-Based Live Recombinant Avian Vaccine, in Particular Against Gumboro Disease U.S. Patent US005733554A; 1998
SinghSM,
BaigentSJ,
PetherbridgeLJ,
SmithLP,
NairVK.
Comparative efficacy of BAC-derived recombinant SB-1 vaccine and the parent wild type strain in preventing replication, shedding and disease induced by virulent Marek's disease virus. Res Vet Sci2010; 89:140–145 [View Article][PubMed]
SchumacherD,
TischerBK,
FuchsW,
OsterriederN.
Reconstitution of Marek's disease virus serotype 1 (MDV-1) from DNA cloned as a bacterial artificial chromosome and characterization of a glycoprotein B-negative MDV-1 mutant. J Virol2000; 74:11088–11098 [View Article][PubMed]
NiikuraM,
KimT,
SilvaRF,
DodgsonJ,
ChengHH.
Virulent Marek's disease virus generated from infectious bacterial artificial chromosome clones with complete DNA sequence and the implication of viral genetic homogeneity in pathogenesis. J Gen Virol2011; 92:598–607 [View Article][PubMed]
AradU.
Modified Hirt procedure for rapid purification of extrachromosomal DNA from mammalian cells. Biotechniques1998; 24:760–762 [View Article][PubMed]
GarciaM,
SpatzSJ,
ChengY,
RibletSM,
VolkeningJD et al. Attenuation and protection efficacy of ORF C gene-deleted recombinant of infectious laryngotracheitis virus. J Gen Virol2016; 97:2352–2362 [View Article][PubMed]
SambrookJ,
RussellDW.
Preparation of plasmid DNA by alkaline lysis with sodium dodecyl sulfate. Molecular cloning: A Laboratory Manual New York: Cold Spring Har Protoc; 2006 pp 11–14
SaraswatM,
GrandRS,
PatrickWM.
Desalting DNA by drop dialysis increases library size upon transformation. Biosci Biotechnol Biochem2013; 77:402–404 [View Article][PubMed]
SlacumG,
HeinR,
LynchR.
The compatibility of HVT recombinants with other Marek’s disease vaccine. 58th Western Poultry Disease Conference285 Sacramento, CA: 2009
SchatKA.
History of the first-generation Marek's disease vaccines: the science and little-known facts. Avian Dis2016; 60:715–724 [View Article][PubMed]
WitterRL.
Protection by attenuated and polyvalent vaccines against highly virulent strains of Marek's disease virus. Avian Pathol1982; 11:49–62 [View Article][PubMed]
CalnekBW,
SchatKA,
PeckhamMC,
FabricantJ.
Field trials with a bivalent vaccine (HVT and SB-1) against Marek's disease. Avian Dis1983; 27:844–849 [View Article][PubMed]
WitterRL,
SharmaJM,
ChaseWB,
HalvorsonDA,
SivanandanV.
Field trials to test the efficacy of polyvalent Marek's disease vaccines in layer and broiler breeder chickens. Poult Sci1985; 64:2280–2286 [View Article][PubMed]
IzumiyaY,
JangHK,
OnoM,
MikamiT.
A complete genomic DNA sequence of Marek’s disease virus type 2, strain HPRS24. Marek’s Disease New York: Springer-Verlag; 2001 pp 191–221
IsfortR,
JonesD,
KostR,
WitterR,
KungHJ.
Retrovirus insertion into herpesvirus in vitro and in vivo. Proc Natl Acad Sci U S A1992; 89:991–995 [View Article][PubMed]
IsfortRJ,
QianZ,
JonesD,
SilvaRF,
WitterR et al. Integration of multiple chicken retroviruses into multiple chicken herpesviruses: herpesviral gD as a common target of integration. Virology1994; 203:125–133 [View Article][PubMed]
LupianiB,
LeeLF,
KreagerKS,
WitterRL,
ReddySM.
Insertion of reticuloendotheliosis virus long terminal repeat into the genome of CVI988 strain of Marek's disease virus results in enhanced growth and protection. Avian Dis2013; 57:427–431 [View Article][PubMed]
BublotM,
Hurley-BaconA,
HughesT,
SilvaM,
MebatsionT et al. Development of a new safe and efficacious Marek's disease vaccine containing a REV LTR insert in its genome. 11th International Symposium on Marek's Disease and Avian Herpesviruses Tours, France: 2016